Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective

• Published in: PharmacoEconomics 2021-11, Vol.39 (11), p.1343-1354
• Main Authors: Alsumali, Adnan, Djatche, Laurence M, Briggs, Andrew, Liu, Rongzhe, Diakite, Ibrahim, Patel, Dipen, Wang, Yufei, Lautsch, Dominik
• Format: Article
• Language: English
• Subjects: Adults; Aged; Angiotensin Receptor Antagonists; Cardiac output; Clinical outcomes; Cost benefit analysis; Costs; Diuretics; Economics; Ejection fraction; Health Administration; Health aspects; Health Economics; Heart failure; Heart Failure - drug therapy; Heterocyclic Compounds, 2-Ring; Hospitalization; Humans; Markov chains; Measurement; Medicare; Medicine; Medicine & Public Health; Methods; Mortality; Original; Original Research Article; Patients; Pharmacoeconomics and Health Outcomes; Prevention; Public Health; Pyrimidines; Quality of Life Research; Quality-Adjusted Life Years; Risk factors; Stroke Volume; United States
• ISSN: 1170-7690; 1179-2027
• DOI: 10.1007/s40273-021-01091-w

Objective Given the high economic burden of disease among adult patients with chronic heart failure with reduced ejection fraction (HFrEF) following a worsening heart failure event in the US, this study aimed to estimate the cost effectiveness of vericiguat plus prior standard-of-care therapies (PSoCT) versus PSoCT alone from a US Medicare perspective. Methods A four-state Markov model (alive prior to heart failure hospitalization, alive during heart failure hospitalization, alive post-heart failure hospitalization, and death) was developed to predict clinical and economic outcomes, based on the results of the VICTORIA trial, in which patients with chronic HFrEF following a worsening heart failure were randomized to placebo or vericiguat, in addition to PSoCT, which consisted of β-blockers, renin-angiotensin-aldosterone inhibitors, mineralocorticoid receptor antagonists, and the angiotensin receptor–neprilysin inhibitor sacubitril/valsartan. Risks of heart failure hospitalization and cardiovascular mortality were based on multivariable regression models derived from VICTORIA data. Utilities were derived from VICTORIA EQ-5D data and the literature. Costs included drug acquisition, heart failure hospitalization, routine care, and terminal care. Primary outcomes included heart failure hospitalization, cardiovascular mortality, life-years, quality-adjusted life-years (QALYs), and incremental costs per QALY gained over a 30-year lifetime horizon, discounted at 3.0% annually. Results For the VICTORIA overall intent-to-treat population, compared with PSoCT, vericiguat plus PSoCT resulted in 19 fewer heart failure hospitalizations and 13 fewer cardiovascular deaths per 1000 patients, as well as 0.28 QALY gained per patient at an incremental cost of $23,322, leading to $82,448 per QALY gained. Conclusions Based on the results of VICTORIA, patients treated with vericiguat had lower rates of heart failure hospitalization and cardiovascular death. The addition of vericiguat to PSoCT was estimated to increase QALYs and to be cost effective at a willingness-to-pay threshold of $100,000 per QALY gained.